Trial Profile

An Open-label Extension Trial to Investigate the Long-term Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 11 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cannabidiol (Primary)
Indications Rett syndrome
Focus Adverse reactions
Acronyms ARCH
Sponsors GW Research; Jazz Pharmaceuticals Inc

Most Recent Events

03 Aug 2021 Status changed from suspended to discontinued.
11 May 2020 Status changed from recruiting to suspended.
11 May 2020 According to a GW Pharmaceuticals media release, recruitment temporarily on hold due to COVID-19 crisis

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com